TriLink BioTechnologies to Expand Manufacturing Capabilities

TriLink BioTechnologies announced the expansion of its messenger RNA (mRNA) manufacturing capabilities on May 24, 2023. The new construction of the current good manufacturing practice (CGMP)-grade facility will help the company with its mission to advance the field as more mRNA-based therapeutics and vaccines enter later-stage clinical trials, according to the company press release.

Further, the new CGMP facility is expected to contribute to the development of mRNA therapeutics, with a building designed for the CGMP manufacture of mRNA-based in-vivo gene editing, gene-edited cell therapies, protein replacement therapies, cancer vaccines, and infectious disease vaccines.

“The expansion of our CGMP mRNA manufacturing capabilities marks a major milestone for TriLink and our partners,” said Becky Buzzeo, chief commercial officer at Maravai LifeSciences, in a press release. “Drug developers will soon be able to leverage our team’s 25-plus years of industry expertise, helping to take critical therapeutics from concept to plasmid DNA through to late-phase clinical mRNA drug substance manufacturing with ease.”

The facility will include ISO 7 cleanrooms and increased mRNA capacity, which will also feature comprehensive in-house analytical services, according to the press release.

“Our team took great care in building and designing our new facility– it’s truly been a labor of love,” added Rob Carpenter, vice president of Engineering at TriLink, in a press release. “In addition to having access to a state-of-the-art facility, developers will also have a direct line to our experienced team to help with process optimization, scale-up, validation, and qualification capabilities.”

Source: TriLink Biotechnologies